Clinical trial

HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy

NCT05322720

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2022-04-01

PhasePHASE2

Study timeline

Study start (estimated)2022-04-01Date precision: month

Registry last updated2022-04-12

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Solid Tumor, Adultunresolved

Interventions

EOC202BIOLOGICAL

albumin-bound paclitaxelDRUG

Sponsors & collaborators

Taizhou EOC Pharma Co., Ltd.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05322720 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.